Impact of CMV Status on HIV Viral Load Decay

NCT03349359 | Completed

• 1 other identifier: CRC_GHN_2017_006
• Study Type: observational
• Target: 345
• Locations: 1 country
• Sites: 1

Brief Summary

Background: Cytomegalovirus (CMV) infection is usually observed among patients with HIV infection. No study to date has investigated the impact of CMV infection on HIV viral load decay during antiretroviral therapy. Methods: 345 consecutive HIV patients coinfected (N=300) or not (N=45) with CMV were enrolled. Clinical, biological and virological data were collected from HIV antiretroviral therapy initiation to the day of HIV viral load undetectability if any.

Conditions

Hiv

Outcome Measures

Primary Outcomes (1)

• HIV viral load undetectability

  HIV viral load was assessed during the follow-up visits after the initiation of antiretroviral therapy. HIV undetectability was defined by an HIV-RNA level \<50 copies/mL.

  From date of HIV therapy initiation until the date of HIV viral load undetectability (12 weeks in average after treatment initiation)

Interventions

HIV antiretroviral therapy DRUG

HIV patients are receiving an antiretroviral therapy according to the physician's discretion and the availability of drugs

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

HIV-infected patients followed at the Department of Infectious Diseases, Croix-Rousse Hospital, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France between June 2005 and July 2016 starting an antiretroviral treatment and with available CMV serology at treatment initiation.

You may qualify if:

• HIV patients starting an antiretroviral therapy
• CMV serology available at antiretroviral therapy initiation
• HIV viral load assessed at each follow-up visit after treatment initiation

You may not qualify if:

• HIV antiretroviral treatment initiation before June 2005

Sponsors & Collaborators

• Hospices Civils de Lyon: lead

Study Sites (1)

Croix-Rousse Hospital, Hospices Civils de Lyon

Lyon, 69004, France

Location

MeSH Terms

Conditions

Acquired Immunodeficiency Syndrome

Condition Hierarchy (Ancestors)

HIV Infections; Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Slow Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 17, 2017
• First Posted: November 21, 2017
• Study Start: November 1, 2016
• Primary Completion: January 30, 2017
• Study Completion: January 30, 2017
• Last Updated: November 21, 2017

Record last verified: 2017-11

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)